Author: Ning, Jingjing; Shao, Xiaonan; Ma, Yibo; Lv, Darong
Title: Valuable hematological indicators for the diagnosis and severity assessment of Chinese children with community-acquired pneumonia: Prealbumin Document date: 2016_11_28
ID: k7zv6ugc_2
Snippet: Prealbumin (PA) is a nonspecific host defense effector with a half-life of 1.9 days; thus, the serum level of PA can be rapidly reduced during acute infection, especially which would be more obvious with bacterial infections. [4] Gao et al [5] found that PA level was decreased during the bacterial infection in children, whereas there were no obvious reduction in viral infection and control groups. Thus, as a negative acute phase protein, PA can b.....
Document: Prealbumin (PA) is a nonspecific host defense effector with a half-life of 1.9 days; thus, the serum level of PA can be rapidly reduced during acute infection, especially which would be more obvious with bacterial infections. [4] Gao et al [5] found that PA level was decreased during the bacterial infection in children, whereas there were no obvious reduction in viral infection and control groups. Thus, as a negative acute phase protein, PA can be used to identify bacterial or viral infections in children with acute infectious disease. However, the role of PA in children with CAP is still unclear, especially its roles in severity assessment of CAP. Therefore, our study aims to investigate the role of PA in the diagnosis and severity assessment of children with CAP in order to guide clinical decision-making.
Search related documents:
Co phrase search for related documents- acute phase and clinical decision making: 1, 2, 3, 4, 5, 6, 7
- acute phase and clinical decision making guide: 1
- acute phase and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- acute phase and day life: 1
- acute phase and decision making: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute phase and host defense: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute phase and host defense effector: 1
- acute phase and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- acute phase and negative acute phase protein: 1, 2, 3
- acute phase and PA level: 1
- acute phase and PA serum level: 1
- acute phase and serum level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- acute phase and severity assessment: 1, 2, 3, 4, 5, 6, 7
- acute phase and severity diagnosis: 1, 2, 3
- acute phase and viral bacterial infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute phase and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute phase protein and bacterial infection: 1, 2, 3, 4, 5, 6, 7
- acute phase protein and clinical decision making: 1
- acute phase protein and control group: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date